Bio-Techne Stock Forecast, Price & News

-13.29 (-2.99 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume896,491 shs
Average Volume234,750 shs
Market Capitalization$16.80 billion
P/E Ratio94.30
Dividend Yield0.29%
30 days | 90 days | 365 days | Advanced Chart
Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Bio-Techne logo

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.79 out of 5 stars

Medical Sector

208th out of 2,097 stocks

Biological Products, Except Diagnostic Industry

28th out of 198 stocks

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Techne?

Wall Street analysts have given Bio-Techne a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Techne?

Bio-Techne saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 444,900 shares, a decline of 16.6% from the May 13th total of 533,400 shares. Based on an average daily volume of 253,700 shares, the short-interest ratio is presently 1.8 days. Currently, 1.2% of the company's shares are short sold.
View Bio-Techne's Short Interest

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Bio-Techne

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its earnings results on Thursday, May, 6th. The biotechnology company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.55. The biotechnology company earned $243.55 million during the quarter, compared to the consensus estimate of $228.57 million. Bio-Techne had a net margin of 21.74% and a trailing twelve-month return on equity of 13.37%. The firm's revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.39 EPS.
View Bio-Techne's earnings history

How has Bio-Techne's stock been impacted by COVID-19?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TECH stock has increased by 139.2% and is now trading at $431.90.
View which stocks have been most impacted by COVID-19

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Thursday, May 6th. Shareholders of record on Monday, May 17th will be given a dividend of $0.32 per share on Friday, May 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Friday, May 14th.
View Bio-Techne's dividend history

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.29%. Bio-Techne does not yet have a strong track record of dividend growth. The dividend payout ratio of Bio-Techne is 33.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 19.60% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

11 equities research analysts have issued 12-month price objectives for Bio-Techne's shares. Their forecasts range from $320.00 to $490.00. On average, they anticipate Bio-Techne's stock price to reach $405.50 in the next year. This suggests that the stock has a possible downside of 6.1%.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 61, Pay $2.86M)
  • Mr. James T. Hippel, Exec. VP of Fin. & CFO (Age 50, Pay $1.15M)
  • Ms. Brenda S. Furlow, Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 63, Pay $821.24k)
  • Mr. Norman David Eansor, Pres of Protein Sciences Segment (Age 60, Pay $1.08M)
  • Mr. Kim Kelderman, Pres of Diagnostics & Genomics (Age 54, Pay $972.4k)
  • David Clair, Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros, VP of Sales and Marketing
  • Mr. Struan Robertson, VP of HR
  • Mr. Robert M. Gavin, Sr. VP of Analytical Solutions Division (Age 53)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Reagents Division (Age 55)

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

Who are some of Bio-Techne's key competitors?

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.79%), Bamco Inc. NY (3.84%), Brown Capital Management LLC (3.45%), Neuberger Berman Group LLC (3.04%), Ownership Capital B.V. (2.75%) and Jackson Square Partners LLC (2.43%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne

Which major investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Champlain Investment Partners LLC, Conestoga Capital Advisors LLC, Brown Capital Management LLC, Renaissance Technologies LLC, Neuberger Berman Group LLC, Ameriprise Financial Inc., and Thrivent Financial for Lutherans. Company insiders that have sold Bio-Techne company stock in the last year include Alpna Seth, Brenda S Furlow, Charles R Kummeth, James Hippel, and Kim Kelderman.
View insider buying and selling activity for Bio-Techne
or view top insider-selling stocks.

Which major investors are buying Bio-Techne stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, BlackRock Inc., Artemis Investment Management LLP, Bank of New York Mellon Corp, Millennium Management LLC, Point72 Asset Management L.P., William Blair Investment Management LLC, and Ownership Capital B.V.. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $431.90.

How much money does Bio-Techne make?

Bio-Techne has a market capitalization of $16.80 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,300 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., CLINIQA Corporation, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

What is Bio-Techne's official website?

The official website for Bio-Techne is

Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.